No Data
Huaheng Biology (688639.SH): Plans to inquire about the transfer of 1.34% of its shares.
On December 20, Gelonghui reported that Huaheng Biological (688639.SH) announced it plans to participate in the pre-IPO share transfer inquiry of Huaheng Biological (hereinafter referred to as "this inquiry transfer") by the shareholder Ningbo Ruiheyuan Venture Capital Partnership (Limited Partnership); the seller intends to transfer a total of 3,357,844 shares, accounting for 1.34% of Huaheng Biological's total share capital.
Anhui Huaheng Biotechnology to Raise Capital of Two Subsidiaries to Boost Production
Anhui Huaheng Biotechnology's (SHSE:688639) Anemic Earnings Might Be Worse Than You Think
Huaheng Biology: Report of Anhui Huaheng Biotechnology Co., Ltd. for the third quarter of 2024
Anhui Huaheng Biotechnology Co., Ltd. Report for the Third Quarter of 2024
Huaheng Biology (688639.SH): The net income for the first three quarters was 0.17 billion yuan, a year-on-year decrease of 46.9%.
Gelonghui October 28th | Hua Heng Biology (688639.SH) released the third quarter report for 2024, with the company's revenue for the first three quarters reaching 1.539 billion yuan, a year-on-year increase of 12.82%; the net income attributable to the listed company shareholders was 0.17 billion yuan, a year-on-year decrease of 46.9%; and the basic earnings per share was 0.74 yuan.
